US 11,596,659 B2Granted

Compositions and methods for inhibiting the proliferation of pathogenic Escherichia coli

AssigneeIntron Biotechnology, Inc.

InventorsSeong Jun Yoon, Jee Soo Son, In Hwang Kim, Hyoung Rok Paik, Hyun Joo Im, Hyun Jin Yu, Cheol Ahn, Tae Yeol Kim, Soo Youn Jun, Sang Hyeon Kang

Life of this patent

Estimating the term…

patentgrep

Loading patent…

Abstract

A composition for preventing or treating an infection or disease caused by a pathogenic Escherichia coli includes a Myoviridae bacteriophage Esc-COP-18 having an ability to lyse the pathogenic Escherichia coli and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by a pathogenic Escherichia coli includes administering to a subject a Myoviridae bacteriophage and lysing the pathogenic Escherichia coli by the Myoviridae bacteriophage.

Claims8

Dependent claims

A composition for preventing or treating an infection or disease caused by a pathogenic Escherichia coli, comprising:

a Myoviridae bacteriophage Esc-COP-18 having an ability to lyse the pathogenic Escherichia coli and a genome represented by a sequence as set forth in SEQ ID NO:
1 and
a pharmaceutically acceptable carrier,
wherein the Myoviridae bacteriophage Esc-COP-18 has a latent period of 25-35 minutes and a burst size of 145-195 plaque-forming units (PFU)/infected cell and is deposited in the Korean Collection for Type Cultures (KCTC) under accession number KCTC 14028BP;
wherein the Myoviridae bacteriophage Esc-COP-18 has major structural proteins in the sizes of approximately 37 kDa, 48 kDa, 75 kDa, and 135 kDa;
and
wherein the Myoviridae bacteriophage Esc-COP-18 has a concentration of 1×104 pfu/ml to 1×1015.pfu/ml or 1×104 pfu/g to 1×1015 pfu/g.

4 more elements

Dependencies are inferred from the claim text.